Literature DB >> 28074012

Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non-small cell lung cancer.

Cristina Gamell1,2, Twishi Gulati1,2, Yaara Levav-Cohen3, Richard J Young4, Hongdo Do5, Pat Pilling6, Elena Takano7, Neil Watkins8, Stephen B Fox7, Prudence Russell9, Doron Ginsberg10, Brendon J Monahan11, Gavin Wright12,13, Alex Dobrovic5, Sue Haupt1,2, Ben Solomon2,4, Ygal Haupt14,2,15,16.   

Abstract

The tumor suppressor p16INK4a, one protein encoded by the INK4/ARF locus, is frequently absent in multiple cancers, including non-small cell lung cancer (NSCLC). Whereas increased methylation of the encoding gene (CDKN2A) accounts for its loss in a third of patients, no molecular explanation exists for the remainder. We unraveled an alternative mechanism for the silencing of the INK4/ARF locus involving the E3 ubiquitin ligase and transcriptional cofactor E6AP (also known as UBE3A). We found that the expression of three tumor suppressor genes encoded in the INK4/ARF locus (p15INK4b, p16INK4a, and p19ARF) was decreased in E6AP-/- mouse embryo fibroblasts. E6AP induced the expression of the INK4/ARF locus at the transcriptional level by inhibiting CDC6 transcription, a gene encoding a key repressor of the locus. Luciferase assays revealed that E6AP inhibited CDC6 expression by reducing its E2F1-dependent transcription. Chromatin immunoprecipitation analysis indicated that E6AP reduced the amount of E2F1 at the CDC6 promoter. In a subset of NSCLC samples, an E6AP-low/CDC6-high/p16INK4a-low protein abundance profile correlated with low methylation of the gene encoding p16INK4a (CDKN2A) and poor patient prognosis. These findings define a previously unrecognized tumor-suppressive role for E6AP in NSCLC, reveal an alternative silencing mechanism of the INK4/ARF locus, and reveal E6AP as a potential prognostic marker in NSCLC.
Copyright © 2017, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28074012     DOI: 10.1126/scisignal.aaf8223

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  9 in total

1.  Proteotranscriptomic Measurements of E6-Associated Protein (E6AP) Targets in DU145 Prostate Cancer Cells.

Authors:  Twishi Gulati; Cheng Huang; Franco Caramia; Dinesh Raghu; Piotr J Paul; Robert J A Goode; Simon P Keam; Scott G Williams; Sue Haupt; Oded Kleifeld; Ralf B Schittenhelm; Cristina Gamell; Ygal Haupt
Journal:  Mol Cell Proteomics       Date:  2018-02-20       Impact factor: 5.911

2.  Uncovering a novel pathway for p16 silencing: Therapeutic implications for lung cancer.

Authors:  C Gamell; T Gulati; B Solomon; S Haupt; Y Haupt
Journal:  Mol Cell Oncol       Date:  2017-03-07

Review 3.  HECT E3 ubiquitin ligases - emerging insights into their biological roles and disease relevance.

Authors:  Yaya Wang; Diana Argiles-Castillo; Emma I Kane; Anning Zhou; Donald E Spratt
Journal:  J Cell Sci       Date:  2020-04-07       Impact factor: 5.285

4.  E6AP promotes prostate cancer by reducing p27 expression.

Authors:  Dinesh Raghu; Piotr Jan Paul; Twishi Gulati; Siddhartha Deb; Christine Khoo; Andrea Russo; Enzo Gallo; Giovanni Blandino; Ai-Leen Chan; Elena Takano; Shahneen K Sandhu; Stephen B Fox; Scott Williams; Sue Haupt; Cristina Gamell; Ygal Haupt
Journal:  Oncotarget       Date:  2017-06-27

5.  Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA).

Authors:  Zipei Cao; Lijuan Wei; Weizhi Zhu; Xuping Yao
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

6.  Novel Insights into the Role of UBE3A in Regulating Apoptosis and Proliferation.

Authors:  Lilach Simchi; Julia Panov; Olla Morsy; Yonatan Feuermann; Hanoch Kaphzan
Journal:  J Clin Med       Date:  2020-05-22       Impact factor: 4.241

7.  E6AP Promotes a Metastatic Phenotype in Prostate Cancer.

Authors:  Cristina Gamell; Ivona Bandilovska; Twishi Gulati; Arielle Kogan; Syer Choon Lim; Zaklina Kovacevic; Elena A Takano; Clelia Timpone; Arjelle D Agupitan; Cassandra Litchfield; Giovanni Blandino; Lisa G Horvath; Stephen B Fox; Scott G Williams; Andrea Russo; Enzo Gallo; Piotr J Paul; Catherine Mitchell; Shahneen Sandhu; Simon P Keam; Sue Haupt; Des R Richardson; Ygal Haupt
Journal:  iScience       Date:  2019-11-02

Review 8.  Exploring the Roles of HERC2 and the NEDD4L HECT E3 Ubiquitin Ligase Subfamily in p53 Signaling and the DNA Damage Response.

Authors:  Nicholas A Mathieu; Rafael H Levin; Donald E Spratt
Journal:  Front Oncol       Date:  2021-03-31       Impact factor: 6.244

Review 9.  Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling.

Authors:  Anmol Sharma; Heena Khan; Thakur Gurjeet Singh; Amarjot Kaur Grewal; Agnieszka Najda; Małgorzata Kawecka-Radomska; Mohamed Kamel; Ahmed E Altyar; Mohamed M Abdel-Daim
Journal:  Int J Mol Sci       Date:  2021-11-04       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.